Eledon Pharmaceuticals (ELDN) Guggenheim SMID Cap Biotech Conference summary

Company overview and strategic focus

• Focused on transplant immunosuppression, shifting from ALS to transplant due to strong preclinical data, large market size, and concentrated market structure.

• Tegoprubart, an anti-CD40 ligand, is the lead asset, aiming to replace tacrolimus as the standard of care in kidney transplantation.

• Market opportunity is significant, with tacrolimus and cyclosporine historically generating multi-billion dollar sales.

• Transplant market is rare disease-like, requiring a small, targeted sales force.

• Data in ALS provided biomarker validation, but the main focus is now on transplant indications.

Clinical development and data highlights

• Phase I-B kidney transplant study showed mean eGFR around 70, about 20 points higher than standard of care with tacrolimus.

• Phase II trial is ongoing, designed to show superiority to tacrolimus, with data expected in Q4; phase I-B update expected in Q3.

• Phase II is powered to detect a nine-point eGFR difference, which could reduce organ loss risk by 25% over 10 years.

• No observed nephrotoxicity, hypertension, hyperglycemia, or CNS toxicity in over 100 patients to date.

• FDA may consider iBox, an algorithm based on eGFR, as a primary endpoint for future trials.

Regulatory and commercial considerations

• Approval likely requires demonstrating superiority in endpoints predicting longer organ survival.

• A single phase III trial will be needed after phase II, with similar design but larger scale.

• U.S. law ensures all transplant patients have access to immunosuppressants, supporting broad coverage.

• Commercial infrastructure can be lean due to the concentrated nature of transplant centers.

• Global commercialization is planned, with trials already running across multiple continents.